# Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

> **NCT05463354** · PHASE2 · COMPLETED · sponsor: **WestVac Biopharma Co., Ltd.** · enrollment: 410 (actual)

## Conditions studied

- COVID-19
- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** Recombinant COVID-19 Vaccine (Sf9 Cell)
- **BIOLOGICAL:** COVID-19 Vaccine (Vero Cell), Inactivated

## Key facts

- **NCT ID:** NCT05463354
- **Lead sponsor:** WestVac Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-11
- **Primary completion:** 2022-08-18
- **Final completion:** 2024-01-26
- **Target enrollment:** 410 (ACTUAL)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05463354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05463354, "Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05463354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*